Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs Neurocrine Biosciences Inc — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.73, while Neurocrine Biosciences Inc trades at $152.5 (market cap $16.46B). Which is the better fit depends on your goals.
| AMDY | NBIX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $185.50 |
52-Week Low | $29.80 | $123.10 |
Market Cap | — | $16.46B |
Enterprise Value | — | $16.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
